Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short Course ADT and SBRT vs SBRT Alone for Prostate Cancer
NCT03056638Phase 3Terminated
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2017
- Primary completion
- Aug 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of degarelix in prostate cancer (PCa) (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Number of Patients With a Positive Biopsy at 2 years. Started Mar 2017; status: terminated.
02
Drugs
degarelix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03056638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03056638.